Mechanisms of resistance to the partner drugs of artemisinin in the malaria parasite
Date
2018
Authors
Martin, Rowena
Shafik, Sarah
Richards, Sashika
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
Abstract
The deployment of artemisinin-based combination therapies (ACTs) has been, and continues to be, integral to reducing the number of malaria cases and deaths. However, their efficacy is being increasingly jeopardized by the emergence and spread of parasites that are resistant (or partially resistant) to the artemisinin derivatives and to their partner drugs, with the efficacy of the latter being especially crucial for treatment success. A detailed understanding of the genetic determinants of resistance to the ACT partner drugs, and the mechanisms by which they mediate resistance, is required for the surveillance of molecular markers and to optimize the efficacy and lifespan of the partner drugs through resistance management strategies. We summarize new insights into the molecular basis of parasite resistance to the ACTs, such as recently-uncovered determinants of parasite susceptibility to the artemisinin derivatives, piperaquine, lumefantrine, and mefloquine, and outline the mechanisms through which polymorphisms in these determinants may be conferring resistance.
Description
Keywords
Citation
Collections
Source
Current Opinion in Pharmacology
Type
Journal article
Book Title
Entity type
Access Statement
License Rights
DOI
10.1016/j.coph.2018.07.010
Restricted until
2037-12-31